Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 03, 2025 09:15 ET | Source: Longeveron

Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum

Longeveron Chief Science Officer and Chief Medical Officer selected as speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum (Dec 8-10).
November 17, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx Collaborates with Breakthrough T1D to Make “Immune-Cloaked” and Safety Switch-Enabled Allogeneic Cell Line for Type 1 Diabetes Therapies

Pluristyx and Breakthrough T1D partner to engineer an immune-cloaked, safety-enabled iPSC line to advance universal islet therapies for type 1 diabetes.
November 05, 2025 07:02 ET | Source: Pluristyx, Inc.

Pluristyx Executes Key Commercial Clinical Use Licenses for iPSC Portfolio, Enabling Novel Therapies for Regenerative Medicine and Neurological Disease Therapeutics

Pluristyx signs key clinical use licenses for its iPSC platform, enabling new regenerative and neurological disease therapies.
September 24, 2025 10:07 ET | Source: Pluristyx, Inc.

Pluristyx and Solesis Announce Strategic Collaboration to Advance Organoid and Cell Therapy Solutions

Pluristyx and Solesis partner to launch game-changing standardized organoid kits, powered by iPSC and polymer technologies.
September 22, 2025 06:20 ET | Source: CELLPROTHERA

CellProthera annonce la publication de ses résultats de phase I/IIb sur la sécurité et la faisabilité des ProtheraCytes® chez des patients souffrant d'insuffisance cardiaque sévère après un infarctus du myocarde.

La publication du JACC-Heart Failure souligne la haute qualité de l'expansion cellulaire, la bonne tolérance, le risque procédural gérable et les signes précoces encourageants d'effets fonctionnels. ...
September 22, 2025 06:20 ET | Source: CELLPROTHERA

CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction

JACC-Heart Failure publication highlights high-quality cell expansion, good tolerability, manageable procedural risk and encouraging early signals of functional effects. Mulhouse, France – [DATE] –...
September 04, 2025 07:07 ET | Source: Pluristyx, Inc.

Pluristyx and BioLamina Announce Strategic Partnership to Accelerate Development of Stem Cell-Based Therapies

Pluristyx & BioLamina partner to accelerate iPSC-based therapies with integrated cell culture solutions, for consistency, scalability & clinical success.
August 13, 2025 16:05 ET | Source: Longeveron

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated...
July 21, 2025 09:15 ET | Source: Longeveron

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

Longeveron licenses patented stem cell technology from the University of Miami.
July 08, 2025 09:15 ET | Source: Longeveron

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.